Key facts
- This page summarizes John E. Imhoff's Form 4 filing for GUIDED THERAPEUTICS INC (GTHP).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 06 Sep 2024, 17:33.
John E. Imhoff - 09 Jul 2024 Form 4 Insider Report for GUIDED THERAPEUTICS INC (GTHP)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- GTHP
- Reported as of
- 09 Jul 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Sep 2024, 17:33:01 UTC
- Prior SEC filing
- 19 Apr 2024
- Next SEC filing
- 01 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ John E. Imhoff
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John E. Imhoff filed Form 4 for GUIDED THERAPEUTICS INC (GTHP) on 06 Sep 2024.
Change
- Previous filing in this sequence was filed on 19 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GTHP
transaction
Derivative
Stock Options
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- +67%
- Price
- $0.000000
- Shares after
- 250,000
- Date
- 09 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $0.1200
- Footnotes
- F1
GTHP
transaction
Derivative
Warrants
Other
- Transaction value
- Shares
- +25,000
- Change %
- Price
- Shares after
- 25,000
- Date
- 31 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $0.2500
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
One-fourth of the shares subject to the award vested on July 9, 2024; the remaining shares will vest monthly, starting on October 9, 2024, subject to the reporting person's continued service on each such date, until the award is fully vested on July 8, 2027.
Footnote F2
On July 31, 2024, the Company issued a $25,000 note payable to Mr. Imhoff. In conjunction with the note, the Company also issued four-year warrants to purchase an aggregate of 25,000 shares of Common Stock at $0.25 per share.